Literature DB >> 29699902

Intravenous leiomyomatosis of the uterus: A clinicopathologic analysis of 13 cases with an emphasis on histogenesis.

Lanlan Tang1, Bingjian Lu2.   

Abstract

The object of this study is to investigate the prognosis and potential histologic origin of uterine intravenous leiomyomatosis (IVL). We retrospectively analyzed the clinicopathologic and immunohistochemical features of 13 cases of IVL from a single institute. The patients underwent hysterectomy (3 with bilateral salpingo-oophorectomy, and 8 with excision of the broad ligaments and/or parametrium). They survived with no evidence of disease for 6-90 months. Intravascular worm-like plugs were macroscopically identified in the myometrium in 10 of 13 cases (76.9%). Six patients (46.1%) had extra-uterine involvement. Histopathologically, the intravascular tumor foci were covered with endothelium. We found the presence of congested vessels in the tumor and the surrounding myometrium in 9 of 13 cases (69.2%). The concurrent entities included seven uterine leiomyomas, one leiomyoma with adenomyosis, one adenomyosis, and one pulmonary benign metastasizing leiomyoma. Estrogen receptor and desmin were positive in IVL, and negative in the vascular wall. We conclude that IVL confined to the uterus may have a favorable prognosis, and we believe IVL is likely to originate from contiguous leiomyoma or myometrium.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Histogenesis; Immunohistochemistry; Prognosis; Uterus; intravenous leiomyomatosis (IVL)

Mesh:

Year:  2018        PMID: 29699902     DOI: 10.1016/j.prp.2018.04.011

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Intravenous leiomyomatosis without extrapelvic involvement.

Authors:  Rodrigo Pereira Mata; Cecília Urzal; Ana Isabel Belo; Fernando Guerreiro
Journal:  BMJ Case Rep       Date:  2020-03-18

2.  Clinical analysis of uterine intravenous leiomyomatosis: A retrospective study of 260 cases.

Authors:  Jing Peng; Fangfang Zhong; Yuemeng Zhu; Mingxing Zhang; Meng Zhang; Chong Lu; Yumeng Wang; Xingling Qi; Congwen Wang; Guiling Li
Journal:  J Obstet Gynaecol Res       Date:  2021-09-15       Impact factor: 1.697

3.  Identification of the molecular relationship between intravenous leiomyomatosis and uterine myoma using RNA sequencing.

Authors:  Xu Zhang; Liangcai Wu; Rongjian Xu; Chengpei Zhu; Guotao Ma; Chaoji Zhang; Xingrong Liu; Haitao Zhao; Qi Miao
Journal:  Sci Rep       Date:  2019-02-05       Impact factor: 4.379

Review 4.  Intravenous leiomyomatosis: Case series and review of the literature.

Authors:  Na Liu; Yan Long; Yun Liu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

5.  Computed tomography evaluation of extensive intravenous angioleiomyoma: a case report.

Authors:  Rui Sun; Hongwei Guan; Hui Li; Yixuan Bai; Fei Wang; Changzhong Li
Journal:  BMC Med Imaging       Date:  2020-02-07       Impact factor: 1.930

6.  Intravenous Leiomyomatosis Complicated by Arteriovenous Fistula: Case Series and Literature Review.

Authors:  Haoxuan Kan; Yang Cao; Yuexin Chen; Yuehong Zheng
Journal:  Front Cardiovasc Med       Date:  2022-06-13

7.  Diagnostic value of contrast-enhanced ultrasound in intravenous leiomyomatosis: a single-center experiences.

Authors:  Zhitong Ge; Yahong Wang; Ying Wang; Song Fang; Hongyan Wang; Jianchu Li
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

8.  An unusual case of intravenous leiomyomatosis involving the right atrium.

Authors:  Min Li; Chen Guo; Yong-Hui Lyu; Ming-Bo Zhang; Zhi-Lu Wang
Journal:  Chin Med J (Engl)       Date:  2019-02       Impact factor: 2.628

9.  Intravenous Leiomyomatosis of the Uterus: A Retrospective Single-Center Study in 14 Cases.

Authors:  Qingbo Su; Xiquan Zhang; Hui Zhang; Yan Liu; Zhaoru Dong; Guangzhen Li; Xiangjiu Ding; Yang Liu; Jianjun Jiang
Journal:  Biomed Res Int       Date:  2020-02-14       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.